RESEARCH TRIANGLE PARK – The new look GSK disclosed its latest quartertly financials early Wednesday, and CEO Emma Walmsley discusses the results in a video.
“This is GSK’s first set of results as a newly focused biopharma company, and we have delivered an excellent second quarter performance, with strong growth in Specialty Medicines, including HIV, and a record quarter for our shingles vaccine Shingrix,” Walmsley said in a statement.
“With this momentum in sales and operating profit growth, we have raised our full-year guidance and are confident in delivering the long-term growth outlooks we set out for shareholders last year.
“We continue to strengthen our pipeline, notably with very positive high-level results from our late-stage RSV [respiratory syncytial virus] vaccine candidate, together with targeted business development acquisitions of Sierra Oncology and Affinivax. These improvements in R&D and operating performance, together with a strengthened post-demerger balance sheet, create new capacity and flexibility for GSK to invest in growth and innovation for patients and shareholders.”
Check out the Reuters report on GSK’s performance and plans.
GSK maintains significant operations in the Research Triangle region.
Watch Walmsley’s update at YouTube:
More GSK news:
‘The new GSK’ emerges with consumer health biz spinoff – but was it the right move?
